Go beyond detection to sustained lung cancer success.

An incidental lung finding is a call to action. Eon Lung translates identified disease into coordinated follow-up, sustained surveillance, and completed care.

Request a demo

Detection is straightforward. What comes after is hard to master.

The journey from finding to treatment takes time, collaboration, and most of all – care.

Identification is only the first step.

Lung findings are being surfaced at unprecedented scale across imaging. But identification alone does not ensure patients receive timely, appropriate follow-up.

Data validation can’t scale without support.

Before care can move forward, teams must review findings, assess risk, and determine next steps. As volumes grow, this effort compounds and becomes harder to sustain.

Surveillance efforts have to adapt to complete needed care.

Long-term surveillance is complex and unpredictable. Patients often require years of follow-up, and missed exams, delayed orders, or evolving risk can disrupt care plans and risk later-stage diagnosis.

Create a clearer pathway to achieving your lung care outcomes.

Find more cancers at Stage I, not Stage IV.

Detect disease
earlier

Ensure high-risk patients receive immediate intervention.

Drive adherence

Automate standardized follow-up workflows.

Reduce admin burden

Convert early detection into downstream care opportunities.

Care for more patients

Efficiently identify, track, and manage more patients – with the same team you have today.

Identify Patients

PRECISION IDENTIFICATION™

Clinical intelligence you can act on immediately

There’s data and there’s truth. While most AI extracts general findings, Eon’s disease-specific models deliver >99% precision across 50+ clinical markers, ensuring care teams can trust what they see and act with confidence.

Validate Data

SMART VALIDATION™

Turn AI from human supervision to trustworthy automation

Every clinical AI output requires human validation. Eon reduces the manual burden of this effort down to a fraction of the time, giving navigators hours back for patient care—not data review.

Determine Follow-up

INTELLIGENT CARE PLANS

Evidence-based follow-up recommendations, instantly delivered

Radiology reports aren’t roadmaps—nearly half of them omit a clear next step. When one is present, Eon incorporates it into the care plan. When it isn’t, Eon leverages validated findings to generate an evidence-based care plan that you can activate in one click.

Monitor Adherence

FOLLOW-UP LISTENER™

Dynamic follow-up that adapts to the unexpected

Most systems track what’s expected. Eon detects the unexpected—new imaging, evolving risk, stalled care—and automatically adapts the care plan to clinical circumstances, flagging the record for navigator action.

Drive Performance

EON INSIGHTS

Capture the insights that drive better care

Like incidental findings, critical data can be buried in reports or tracked in disparate ways across sites. Eon gives clinical, operational, and executive teams the visibility they need to measure program impact and support patient outcomes systemwide.

The tech to manage every nodule. The team to help bring patients back for care.

Eon's Care Management team helps manage lower-risk patients so your team can focus on complex, high-priority care.

Learn More

Health system leaders are transforming lung cancer outcomes with Eon.

"Last fiscal year we identified roughly 7,100 incidental pulmonary nodules. With Eon, we're on track for almost 18,000 this year. Without Eon’s Care Management, we would be a broken system."

Parker Harris, CEO of Baptist Memorial Hospital-Tipton

"Since our Eon go-live, we've diagnosed 260 lung cancers just through early detection... and doubled the amount of Stage I and II cases in our system."

Emily Cassidy, MD, Thoracic Surgeon, Our Lady of the Lake

70% of cancers diagnosed in Stage 1 or Stage II

Over 50% reduction in time-to-treatment

$3.44M in new direct margin

90% of cancer patients returned for in-network care

147% reduction in time-to-recommended-next-step
(34 days to 5 days)

247% growth in thoracic oncology referrals

89% of incidental pulmonary nodule patients returned for follow-up

4 months to break-even ROI

Eon drives screening efficiency so you can manage the incidentals you aren't today.

“We’ve found the time it takes to review lung cancer screening exam results and move patients into their care pathway has gone from approximately six minutes to about ninety seconds."

Cindy Lambdin, RN, MS Nurse Manager, Lung Cancer Screening, Henry Ford Health

Go beyond detection to sustained lung cancer success.

Detection is straightforward. What comes after is hard to master.

Identification is only the first step.

Data validation can’t scale without support.

Surveillance efforts have to adapt to complete needed care.

Create a clearer pathway to achieving your lung care outcomes.

Efficiently identify, track, and manage more patients – with the same team you have today.

Clinical intelligence you can act on immediately

Turn AI from human supervision to trustworthy automation

Evidence-based follow-up recommendations, instantly delivered

Dynamic follow-up that adapts to the unexpected

Capture the insights that drive better care

The tech to manage every nodule. The team to help bring patients back for care.

Health system leaders are transforming lung cancer outcomes with Eon.

70% of cancers diagnosed in Stage 1 or Stage II

Over 50% reduction in time-to-treatment

$3.44M in new direct margin

90% of cancer patients returned for in-network care

147% reduction in time-to-recommended-next-step
(34 days to 5 days)

247% growth in thoracic oncology referrals

89% of incidental pulmonary nodule patients returned for follow-up

4 months to break-even ROI

Eon drives screening efficiency so you can manage the incidentals you aren't today.

“We’ve found the time it takes to review lung cancer screening exam results and move patients into their care pathway has gone from approximately six minutes to about ninety seconds."

Get a custom value analysis for your lung care population

Dive deeper into Eon's impact, innovation, and insights on lung care.

How Baptist Scaled Lung Outcomes Without Adding Headcount

Five Lessons for Building a Scalable Lung Nodule Program

How UCHealth Cut Time-to-Treatment and Hit 4-Month ROI

Why "Low-Risk" Lung Nodules Need Surveillance

Go beyond detection to sustained lung cancer success.

Detection is straightforward. What comes after is hard to master.

Identification is only the first step.

Data validation can’t scale without support.

Surveillance efforts have to adapt to complete needed care.

Create a clearer pathway to achieving your lung care outcomes.

Efficiently identify, track, and manage more patients – with the same team you have today.

Clinical intelligence you can act on immediately

Turn AI from human supervision to trustworthy automation

Evidence-based follow-up recommendations, instantly delivered

Dynamic follow-up that adapts to the unexpected

Capture the insights that drive better care

The tech to manage every nodule. The team to help bring patients back for care.

Health system leaders are transforming lung cancer outcomes with Eon.

70% of cancers diagnosed in Stage 1 or Stage II

Over 50% reduction in time-to-treatment

$3.44M in new direct margin

90% of cancer patients returned for in-network care

147% reduction in time-to-recommended-next-step (34 days to 5 days)

247% growth in thoracic oncology referrals

89% of incidental pulmonary nodule patients returned for follow-up

4 months to break-even ROI

Eon drives screening efficiency so you can manage the incidentals you aren't today.

“We’ve found the time it takes to review lung cancer screening exam results and move patients into their care pathway has gone from approximately six minutes to about ninety seconds."

Get a custom value analysis for your lung care population

Dive deeper into Eon's impact, innovation, and insights on lung care.

How Baptist Scaled Lung Outcomes Without Adding Headcount

Five Lessons for Building a Scalable Lung Nodule Program

How UCHealth Cut Time-to-Treatment and Hit 4-Month ROI

Why "Low-Risk" Lung Nodules Need Surveillance

147% reduction in time-to-recommended-next-step
(34 days to 5 days)